Cybin Submits IND Application to FDA for its Phase 1/2a First-in-Human Trial of CYB003 for the Treatment of Major… May 31, 2022
Cybin Announces Successful Completion of In Vivo Preclinical Studies for its Deuterated Psilocybin Analog CYB003… Mar 29, 2022
European Patent Grant Strengthens Small Pharma’s Ketamine-Based Patent Portfolio for the Treatment of Depressive… Oct 25, 2021
Small Pharma Granted Fast-Track Designation From U.K. Regulator for DMT-Assisted Therapy for Major Depressive Disorder Oct 21, 2021
Small Pharma Successfully Completes Phase I Clinical Trial of DMT in Combination with Supportive Psychotherapy Sep 21, 2021
Cybin Files Two Additional International Patent Applications in Support of the Company’s Research Phase Programs Aug 19, 2021
